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José R Quirós46, Marc J Gunter1, Elio Riboli1 and Teresa Norat1Abstract
Background: Cancer survivors are advised to follow lifestyle recommendations on diet, physical activity, and body
fatness proposed by the World Cancer Research Fund/American Institute of Cancer Research (WCRF/AICR) for
cancer prevention. Previous studies have demonstrated that higher concordance with these recommendations
measured using an index score (the WCRF/AICR score) was associated with lower cancer incidence and mortality.
The aim of this study was to evaluate the association between pre-diagnostic concordance with WCRF/AICR
recommendations and mortality in colorectal cancer (CRC) patients.
Methods: The association between the WCRF/AICR score (score range 0–6 in men and 0–7 in women; higher
scores indicate greater concordance) assessed on average 6.4 years before diagnosis and CRC-specific (n = 872)
and overall mortality (n = 1,113) was prospectively examined among 3,292 participants diagnosed with CRC in
the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort (mean follow-up time after
diagnosis 4.2 years). Multivariable Cox proportional hazard models were used to estimate hazard ratios (HRs)
and 95% confidence intervals (CIs) for mortality.
(Continued on next page)* Correspondence: d.romaguera-bosch@imperial.ac.uk
1Department of Epidemiology and Biostatistics, School of Public Health, Imperial
College London, St. Mary’s Campus, Norfolk Place, W2 1PG London, UK
2Instituto de Investigación Sanitaria de Palma (IdISPa), Hospital Universitario
Son Espases, Research Unit I-1, Ctra. de Valldemossa 79, 07010 Palma de
Mallorca, Spain
Full list of author information is available at the end of the article
© 2015 Romaguera et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Romaguera et al. BMC Medicine  (2015) 13:107 Page 2 of 12(Continued from previous page)
Results: The HRs (95% CIs) for CRC-specific mortality among participants in the second (score range in men/
women: 2.25–2.75/3.25–3.75), third (3–3.75/4–4.75), and fourth (4–6/5–7) categories of the score were 0.87
(0.72–1.06), 0.74 (0.61–0.90), and 0.70 (0.56–0.89), respectively (P for trend <0.0001), compared to participants
with the lowest concordance with the recommendations (category 1 of the score: 0–2/0–3). Similar HRs for
overall mortality were observed (P for trend 0.004). Meeting the recommendations on body fatness and plant
food consumption were associated with improved survival among CRC cases in mutually adjusted models.
Conclusions: Greater concordance with the WCRF/AICR recommendations on diet, physical activity, and body
fatness prior to CRC diagnosis is associated with improved survival among CRC patients.
Keywords: Colorectal cancer, Diet, Healthy lifestyle, Physical activity, Survival, WeightBackground
The number of colorectal cancer (CRC) survivors is
increasing thanks to early detection of tumors and ad-
vanced treatments [1]. Tumor characteristics at diagno-
sis are still the main determinants of survival, although
there is a large variation in survival among patients with
the same tumor stage and grade, and similar access to
treatment. It has been hypothesized that lifestyle factors
before and after diagnosis could influence this variability
in survival [2].
There are only a small number of studies evaluating
the potential role of lifestyle factors on CRC survival. Al-
though results arising from these studies are not always
consistent, most studies point towards a beneficial asso-
ciation of higher levels of physical activity [2-5], a
healthy body weight [2,4,6,7], and consumption of diet-
ary patterns low in red meat with CRC survival [7-10].
Given the lack of conclusive evidence on which life-
style factors may determine survival, the World Cancer
Research Fund/American Institute of Cancer Research
(WCRF/AICR) advice for cancer survivors is to follow
the same recommendations on diet, physical activity,
and body fatness formulated for cancer prevention
[11]. Within the context of the European Prospective
Investigation into Cancer and Nutrition (EPIC) study,
we have constructed an index score to reflect con-
cordance with the WCRF/AICR recommendations for
cancer prevention (the WCRF/AICR score); a higher
WCRF/AICR score was associated with a lower inci-
dence of overall and CRC cancer [12], as well as with
a lower risk of overall and cancer mortality [13], among
EPIC participants free of cancer at baseline.
The aim of the present study was to evaluate the asso-
ciation between concordance with the WCRF/AICR rec-
ommendations for cancer prevention on diet, physical
activity, and body fatness before diagnosis and CRC-
related and all-cause mortality among EPIC participants
diagnosed with CRC during follow-up. We also evalu-
ated the independent association of each component
of the WCRF/AICR score with mortality among CRC
cases.Methods
Study population, CRC ascertainment, and sample selection
CRC cases in this study were identified among partici-
pants from the EPIC cohort, a large prospective study
with over 520,000 participants enrolled in 23 centres
in Denmark, France, Germany, Greece, Italy, the
Netherlands, Norway, Spain, Sweden, and the United
Kingdom between 1992 and 1999. Approval for this
study was obtained from the ethical review boards of the
International Agency for Research on Cancer and from
all local institutions where subjects had been recruited
for the EPIC study. Written informed consent was ob-
tained from all participants before joining the EPIC
study. The EPIC study methods have been described in
detail elsewhere [14,15].
Cancer incidence during follow-up was determined
through record linkage with regional cancer registries
(Denmark, Italian centres except Naples, the Netherlands,
Norway, Spain, Sweden, and the United Kingdom;
complete up to December 2006) or via a combination
of methods, including the use of health insurance re-
cords, contacts with cancer and pathology registries,
and active follow-up through study subjects and their
next-of-kin (France, Germany, the Italian center of
Naples, and Greece; complete up to June 2010). CRC
cases were selected among participants who developed
colon (C18.0-C18.7, according to the Tenth revision
of the International Classification of Diseases, Injuries
and Causes of Death (ICD-10)), rectum (C19-C20),
and overlapping/unspecified origin tumors (C18.8 and
C18.9).
A total of 4,701 CRC cases were identified. Case exclu-
sions included 426 cases diagnosed with CRC after vital
status censoring date, 172 cases with in situ or non-
primary tumors in the colon, 144 non-adenocarcinoma
or tumor of unknown morphology, 21 due to missing
date of death or diagnosis, 74 within the extreme rank-
ing (top and bottom 1%) of the ratio energy intake/
energy requirement, 37 with missing data on anthro-
pometry, 56 with missing data on diet, 338 with
missing data on physical activity (including all participants
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breastfeeding (including all women from Bilthoven). The
final sample included 3,292 CRC cases (1,497 men and
1,795 women; 2,071 colon cancer cases and 1,221 rectal
cancer cases).
Exposure assessment: data collection and dietary
questionnaires
At recruitment (between 1992 and 1999), before cancer
diagnosis, volunteers participating in EPIC filled out
medical, dietary, and lifestyle questionnaires, including
questions on alcohol use, smoking status, physical activ-
ity, education, reproductive history, breastfeeding, ex-
ogenous hormones use, and previous illnesses. Body
weight and height were measured in all centres except
Oxford (health conscious population) and France, where
anthropometry was self-reported [16]. Usual food intakes
were measured using country-specific validated dietary
questionnaires [17] and individual nutrient intakes were
derived from foods included in the dietary question-
naires through the standardized EPIC Nutrient Data
Base [18]. To correct for any systematic under- or over-
estimation of dietary intake between the study centres, a
dietary calibration study was conducted. A random sam-
ple of 36,308 men and women (7.4% of the sample)
completed a detailed computerized 24-h dietary recall,
and nutrient intake was calculated using the standard-
ized EPIC Nutrient Data Base [19]. Dietary exposures
across centres were scaled using an additive calibration
model [17]. Briefly, the difference between the sex- and
center-specific mean of the values from the dietary ques-
tionnaire and the mean of the 24-h recall values was
calculated and added to the questionnaire values. All
dietary variables used in the present study were cali-
brated using additive calibration.
WCRF/AICR score construction
A WCRF/AICR score, incorporating six of the WCRF/
AICR recommendations for men (regarding body fat-
ness, physical activity, food and drinks that promote
weight gain, plant foods, animal foods, and alcoholic
drinks) and seven for women (plus breastfeeding) was
constructed. Detailed information on the operationaliza-
tion of the score was previously published [12] and can
be found in Additional file 1: Table S1. Briefly, we
assigned, for each component, 1 point when the recom-
mendation was met, 0.5 points when it was half met,
and 0 points otherwise. When available, the quantitative
criteria provided in the recommendations were used as
cut-off points and intermediate cut-off points, defined
by the authors, were used otherwise. For the recommen-
dations, including several sub-recommendations (foods
and drinks that promote weight gain or plant foods), the
final score was the average of each sub-recommendationscore (meaning that for these recommendations, plaus-
ible scores were 0, 0.25, 0.5, 0.75, and 1). Three recom-
mendations were not implemented: i) the recommendation
on preservation, processing, and preparation of foods be-
cause of insufficient data available, ii) the recommendation
on dietary supplements which could not be operationalized
in terms of cancer prevention without further assumptions
about type or dose of supplementation, and iii) the special
recommendation related to cancer survivors, who were
advised to follow the same recommendations for cancer
prevention. As the WCRF/AICR recommendations
were not ranked according to priority, all major recom-
mendations were summed to contribute equally to the
total WCRF/AICR score. Therefore, the total WCRF/
AICR score ranged from 0 to 6 for men and from 0 to
7 for women, with higher scores indicating greater con-
cordance with the WCRF/AICR recommendations. The
score was further categorized into four categories ac-
cording to pre-defined cut-off points (0–2, 2.25–2.75,
3–3.75, and 4–6 points in men and 0–3, 3.25–3.75,
4–4.75, and 5–7 points in women).
Outcome assessment: vital status ascertainment
Vital status follow-up was conducted by record linkage
with regional and/or national mortality registries in all
countries except France, Germany, Greece, and the
Italian center of Naples, where data are collected through
an active follow-up. Censoring dates for complete follow-
up were between June 2005 and June 2009 in Denmark,
the Netherlands, Spain, the United Kingdom, Sweden, and
Italian centres except Naples. In Germany, Greece, France,
and Naples, follow-up was based on a combination of
methods, including health insurance records, cancer and
pathology registries, and active follow-up through study
subjects and their next-of-kin. In these centres, the end of
follow-up was defined as the last known date of contact or
the date of death, whichever came first. The last update of
endpoint information occurred between December 2007
and December 2009.
Mortality data were coded according to the ICD-10.
Up to six qualifiers of the cause of death were reviewed.
The outcome of interest for the present study (death
from CRC) was assigned based on the underlying cause
of death [20].
Statistical analyses
Cox proportional hazards regression was used to esti-
mate the association between the WCRF/AICR score
and death from CRC (primary endpoint) or death from
any cause (secondary endpoint). Age was used as the
primary time variable, with entry time defined as the
subject’s age at CRC diagnosis and exit time as age cen-
soring or death. All analyses were stratified by country
to control for country-specific effects such as follow-up
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score was assessed as a continuous variable (1-point
increment) and as a categorical variable (using the four
pre-defined categories). The WCRF/AICR categorical
variable was scored from 1 to 4, and trend tests were calcu-
lated on these scores. Multivariable models were adjusted
for sex, year of CRC diagnosis, educational level (coded as
no education, primary school, technical school, secondary
school, university degree, and unknown/missing), smoking
status (never, former, smoker, missing), tumor site (colon,
rectum), tumor grade (well differentiated, moderately dif-
ferentiated, poorly/undifferentiated, missing), and tumor
stage (I, II, III, IV, missing); based on a previously described
harmonization procedure among different EPIC centres
[20]. Models were further adjusted for ‘lag time’ (years
between recruitment/exposure assessment and CRC
diagnosis), with no change in results; therefore, this vari-
able was not included in the final multivariable models.
Sensitivity analyses were performed excluding partici-
pants who died within 6 months of CRC diagnosis and
excluding participants with incomplete CRC stage data.
Potential effect modifications by sex, mean age at
diagnosis (<64.6 years vs. ≥64.6 years), year of diag-
nosis (1992–2001 vs. 2002–2008), median ‘lag time’
(<6.5 years vs. ≥6.5 years), tumor stage (I, II, III, IV),
tumor site (colon vs. rectum), colon tumor sub-site
(proximal vs. distal), and smoking status (former
smokers, current smokers, and never smokers) were
explored by modelling interaction terms (cross-products)
between these variables (categorically) and the WCRF/
AICR score (continuous), and conducting stratified ana-
lyses. Potential heterogeneity between countries in the as-
sociation between the WCRF/AICR score and CRC-related
mortality and overall mortality was assessed by calculating
country-specific estimates and using random-effect meta-
analyses (I2).
We estimated the independent association of each
component of the WCRF/AICR score with CRC-related
and overall mortality, after adjusting for all other com-
ponents of the score. Finally, we evaluated the relative
importance of each of the components of the WCRF/
AICR score on CRC-related and overall mortality by
subtracting alternately one component at a time from
the original score, and including this component as a co-
variate in the model. To be able to compare the risk esti-
mates to that of the total WCRF/AICR score, these
alternative scores were assessed as continuous variables
per 1 SD increments.
All statistical analyses were conducted using STATA
11 (StataCorp).
Results
Of the 3,292 CRC cases from the EPIC cohort included
in this study, 1,113 died after an average of 4.2 (SD, 3.3)years; 872 deaths were related to CRC. The average time
between recruitment/exposure assessment and CRC
diagnosis (‘lag time’) was 6.4 (3.3) years. The percentage
of deaths was higher in individuals assigned to the
lowest category of the WCRF/AICR score (those whose
lifestyle was least concordant with the recommendations
for cancer prevention) compared to those with higher
WCRF/AICR scores. The percentage of CRC cases that
were smokers at baseline and had a lower educational
level was also higher in lower WCRF/AICR categories
compared to the highest (Table 1).
The hazard ratios (HRs) (95% confidence intervals
(CIs)) for CRC-related and overall mortality according to
categories of the WCRF/AICR score are shown in
Table 2. In multiple adjusted models, those within the
second, third, and fourth categories of the WCRF/AICR
score had a HR (95% CI) for CRC-related mortality of
0.87 (0.72–1.06), 0.74 (0.61–0.90), and 0.70 (0.56–0.89),
respectively (P for trend <0.0001) compared to the first
category (reference category); the corresponding HRs
(95% CI) for overall mortality were 0.89 (0.75–1.06), 0.77
(0.66–0.92), and 0.79 (0.65–0.98) (P for trend 0.004).
Similar HRs for CRC-related mortality were obtained in
models run separately for men and women; however, the
association between categories of the WCRF/AICR
score and overall mortality was only significant in
men (multivariable adjusted P for trend 0.004) but not in
women (multivariable adjusted P for trend 0.242).
A one point increment in the WCRF/AICR score was
associated with a 10% (95% CI, 3–17%) and 7% (95% CI,
1–13%) risk reduction in CRC-related and overall mor-
tality, respectively. Similar HRs for CRC-related and
overall mortality associated with a 1-point increment in
the score were obtained after performing sensitivity ana-
lyses. No evidence of effect modification by any of the
analyzed variables (including sex) was detected (P for
heterogeneity were all statistically not significant);
however, the HRs for both CRC-related and overall
mortality were lower among participants with less
than 6.5 years of follow-up between recruitment and
CRC diagnosis (compared with longer ‘lag time’), rec-
tum cancer (compared to colon cancer), distal colon cancer
(compared to proximal colon cancer), and never smokers
(Table 3).
Similar risk reductions in CRC-related mortality were
observed when each component of the WCRF/AICR
score was removed from the score; however, when the
body fatness component and the breastfeeding compo-
nent were excluded, the association between the score
and CRC-mortality was no longer significant (Table 4).
When the independent association between the com-
ponents of the score and CRC-related and overall
mortality was examined, it was observed that meeting
the recommendations for body fatness and plant food
Table 1 Characteristics of the sample of CRC survivors by categories of WCRF/AICR score
WCRF/AICR score categories
All participants Category 1 Category 2 Category 3 Category 4
Score range (men)/(women) (0–6)/(0–7) (0–2)/(0–3) (2.25–2.75)/(3.25–3.75) (3–3.75)/(4–4.75) (4–6)/(5–7)
No. of participants 3,292 707 964 1,118 503
Age at recruitment, years [mean (SD)] 58.2 (7.6) 57.8 (7.2) 58.1 (7.6) 58.4 (7.6) 58.7 (8.7)
Age at CRC diagnosis, years [mean (SD)] 64.6 (8.0) 64.1 (7.6) 64.7 (7.8) 64.6 (7.8) 65.1 (9.0)
Follow-up time from recruitment to CRC diagnosis,
years [mean (SD)]
6.4 (3.3) 6.3 (3.4) 6.6 (3.3) 6.2 (3.3) 6.3 (3.4)
Follow-up time from CRC diagnosis to end of follow-up,
years [mean (SD)]
4.2 (3.3) 4.1 (3.3) 4.1 (3.2) 4.3 (3.4) 4.3 (3.3)
Deaths due to any cause [n (%)] 1,113 (33.8) 255 (36.1) 333 (34.2) 359 (32.1) 169 (33.6)
Deaths due to CRC [n (%)] 872 (26.5) 206 (29.1) 260 (27.0) 283 (25.3) 123 (24.5)
Tumor stage [%]
I 18.3 19.7 18.4 18.3 16.3
II 18.5 19.2 17.8 18.3 19.5
III 26.2 24.9 28.5 25.8 24.6
IV 10.2 12.7 9.1 9.9 9.5
Unknown 26.7 23.5 26.1 27.7 30.0
Tumor grade [%]
Well differentiated 7.3 8.8 7.9 6.2 6.8
Moderately differentiated 29.0 29.8 29.5 28.9 26.8
Poorly/Undifferentiated 7.6 6.7 8.0 8.6 5.8
Unknown 56.2 54.7 54.7 56.4 60.6
Tumor site [%]
Colon – Proximal 28.9 28.0 28.1 28.2 33.0
Colon – Distal 28.7 30.4 28.8 28.9 25.5
Colon – Unspecified 5.4 4.8 5.7 5.6 5.0
Rectum 37.1 36. 8 37.3 37.3 36.6
Sex [%]
Men 45.5 42.9 45.0 47.4 45.7
Women 54.5 57.1 55.0 52.6 54.3
Educational level [%]
None 5.0 5.5 6.0 4.3 3.6
Primary school 32.8 33.8 34.1 34.8 24.7
Technical school 22.7 23.9 23.6 20.5 24.3
Secondary school 15.4 13.9 14.1 17.1 16.3
University degree 19.8 19.8 18.6 19.4 23.1
Not specified/Unknown 4.3 3.1 3.6 3.9 8.2
Smoking status [%]
Never smokers 41.6 36.6 39.8 43.3 47.9
Former smokers 34.0 32.5 34.1 35.4 32.4
Current smokers 23.5 29.6 25.0 20.6 18.7
Unknown 1.0 1.3 1.0 0.7 1.0
Romaguera et al. BMC Medicine  (2015) 13:107 Page 5 of 12
Table 2 Hazard ratios (HR) and 95% confidence intervals (95% CIs) for CRC-related and overall mortality among CRC
survivors according to categories of the WCRF/AICR score
WCRF/AICR score categories
Category 1 Category 2 Category 3 Category 4 P trend
Score range (men)/(women) (0–2)/(0–3) (2.25–2.75)/ (3.25–3.75) (3–3.75)/(4–4.75) (4–6)/(5–7)
All
CRC-related mortality
No. of deaths (%) 206 (29.1) 260 (27.0) 283 (25.3) 123 (24.5)
Age- and country-adjusteda
HR (95% CI) 1.00 (reference) 0.92 (0.76–1.11) 0.77 (0.64–0.93) 0.72 (0.57–0.91) 0.001
Multivariate adjustedb
HR (95% CI) 1.00 (reference) 0.87 (0.72–1.06) 0.74 (0.61–0.90) 0.70 (0.56–0.89) <0.0001
Overall mortality
No. of deaths (%) 255 (36.1) 330 (34.2) 359 (32.1) 169 (33.6)
Age- and country-adjusteda
HR (95% CI) 1.00 (reference) 0.94 (0.79–1.10) 0.79 (0.67–0.93) 0.79 (0.65–0.97) 0.002
Multivariate adjustedb
HR (95% CI) 1.00 (reference) 0.89 (0.75–1.06) 0.77 (0.66–0.92) 0.79 (0.65–0.98) 0.004
Men
CRC-related mortality
No. of deaths (%) 94 (31.0) 122 (28.1) 130 (24.5) 62 (27.0)
Age- and country-adjusteda
HR (95% CI) 1.00 (reference) 1.01 (0.77–1.34) 0.80 (0.60–1.05) 0.79 (0.56–1.12) 0.050
Multivariate adjustedb
HR (95% CI) 1.00 (reference) 0.92 (0.69–1.22) 0.74 (0.54–0.96) 0.69 (0.48–0.99) 0.009
Overall mortality
No. of deaths (%) 118 (38.9) 162 (37.3) 164 (30.9) 87 (37.8)
Age- and country-adjusteda
HR (95% CI) 1.00 (reference) 1.00 (0.79–1.28) 0.76 (0.59–0.97) 0.78 (0.58–1.06) 0.014
Multivariate adjustedb
HR (95% CI) 1.00 (reference) 0.94 (0.73–1.21) 0.72 (0.56–0.93) 0.71 (0.52–0.97) 0.004
Women
CRC-related mortality
No. of deaths (%) 112 (27.7) 138 (26.0) 153 (26.0) 61 (22.3)
Age- and country-adjusteda
HR (95% CI) 1.00 (reference) 0.86 (0.66–1.11) 0.77 (0.60–0.99) 0.67 (0.48–0.92) 0.008
Multivariate adjustedb
HR (95% CI) 1.00 (reference) 0.81 (0.62–1.06) 0.75 (0.57–0.97) 0.72 (0.51–1.00) 0.027
Overall mortality
No. of deaths (%) 137 (33.9) 168 (31.7) 195 (33.2) 82 (30.0)
Age- and country-adjusteda
HR (95% CI) 1.00 (reference) 0.88 (0.70–1.11) 0.83 (0.67–1.05) 0.78 (0.59–1.03) 0.062
Multivariate adjustedb
HR (95% CI) 1.00 (reference) 0.86 (0.68–1.09) 0.82 (0.65–1.04) 0.88 (0.66–1.18) 0.242
aCox regression model, with age at CRC diagnosis as entry time and age at death or censoring as exit time, stratified by country; bMultivariable adjusted models
were further adjusted for year of CRC diagnosis, tumor stage, tumor grade, tumor site, sex, educational level, and smoking status.
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Table 3 Hazard ratios (HR) and 95% confidence intervals (95% CIs) for CRC-related and overall mortality among CRC
survivors associated with 1-point increment in the WCRF/AICR score; sensitivity and effect modification analyses
CRC-related mortality Overall mortality
No. of deaths (%) HRb 95% CI P for Heter. No. of deaths (%) HRb 95% CI P for Heter.
Age- and country-adjusteda 872 (26.5) 0.92 (0.86–0.98) 1,113 (33.8) 0.92 (0.87–0.97)
Multivariate adjustedb 872 (26.5) 0.90 (0.83–0.97) 1,113 (33.8) 0.93 (0.87–0.99)
Sensitivity analysesc
Excluding deaths within 6 mo of diagnosis 717 (24.4) 0.89 (0.82–0.97) 858 (29.2) 0.92 (0.85–0.99)
Participants with complete CRC stage data 618 (25.6) 0.88 (0.80–0.96) 783 (32.4) 0.91 (0.84–0.98)
Effect modification analysesc
By sex 0.983 0.597
Men 408 (27.3) 0.89 (0.79–1.00) 531 (35.5) 0.90 (0.81–0.99)
Women 464 (25.8) 0.91 (0.82–1.01) 582 (32.4) 0.96 (0.88–1.06)
By mean age at diagnosis
<64.6 years 425 (26.4) 0.89 (0.80–0.99) 0.985 515 (32.0) 0.91 (0.82–0.99) 0.553
≥64.6 years 447 (26.5) 0.92 (0.83–1.03) 598 (35.5) 0.97 (0.89–1.07)
By year of diagnosis
1992–2001 548 (33.5) 0.88 (0.80–0.96) 0.889 691 (42.2) 0.90 (0.82–0.98) 0.415
2002–2008 324 (19.6) 0.93 (0.82–1.06) 422 (25.5) 0.96 (0.86–1.08)
By median ‘lag time’d
<6.5 years 550 (33.3) 0.85 (0.77–0.94) 0.251 687 (41.6) 0.88 (0.81–0.96) 0.094
≥6.5 years 332 (20.2) 0.96 (0.84–1.08) 426 (26.0) 0.99 (0.88–1.10)
By tumor stage
I 51 (8.5) 0.86 (0.62–1.20) 0.279 76 (12.6) 0.80 (0.61–1.04) 0.067
II 78 (12.8) 0.87 (0.68–1.12) 108 (17.7) 0.85 (0.69–1.06)
III 294 (34.1) 0.87 (0.75–1.00) 369 (42.8) 0.94 (0.83–1.07)
IV 195 (57.9) 0.86 (0.72–1.04) 230 (68.2) 0.85 (0.72–1.01)
By tumor site 0.263 0.137
Colon 537 (25.9) 0.95 (0.86–1.05) 693 (33.5) 0.99 (0.90–1.07)
Rectum 355 (29.1) 0.85 (0.75–0.97) 420 (34.4) 0.86 (0.77–0.96)
By colon sub-site 0.490 0.168
Proximal 288 (30.3) 1.07 (0.92–1.25) 310 (32.6) 1.09 (0.95–1.24)
Distal 246 (26.1) 0.81 (0.70–0.94) 301 (31.9) 0.84 (0.73–0.96)
By smoking status 0.892 0.773
Never smoker 365 (26.7) 0.86 (0.77–0.97) 448 (32.7) 0.94 (0.84–1.05)
Former smoker 286 (25.6) 0.91 (0.79–1.05) 372 (33.3) 0.89 (0.79–1.01)
Current smoker 214 (27.6) 1.00 (0.86–1.16) 282 (36.4) 0.96 (0.84–1.10)
aCox regression model, with age at CRC diagnosis as entry time and age at death or censoring as exit time, stratified by country; bMultivariable adjusted models
were further adjusted for year of CRC diagnosis, tumor stage, tumor grade, tumor site, sex, educational level, and smoking status; cSensitivity and stratified
analyses were based on multivariable adjusted model; d‘Lag-time’ means years between recruitment and CRC diagnosis.
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CRC survivors in mutually adjusted models, compared to
those who did not meet the recommendation (Table 5).
We further evaluated the association of individual com-
ponents of the WCRF/AICR score with mortality in
colon and rectal cancer cases separately; in these
analyses, meeting the body fatness recommendationwas associated with improved survival in colon can-
cer cases whereas meeting the plant food recommen-
dation reduced mortality risk in rectal cancer cases
(data not shown).
There was some evidence for heterogeneity between
countries in the association between the WCRF/AICR
score and CRC-related mortality (I2 = 31.9%; P for
Table 4 Hazard ratios (HR) and 95% confidence intervals
(95% CIs) for CRC-related and overall mortality among
CRC survivors associated with one standard deviation (SD)
increment in the WCRF/AICR score after removing each
component of the score at a time
CRC-related
mortality
Overall
mortality
HRa 95% CI HRa 95% CI
WCRF/AICR score 0.90 (0.84–0.97) 0.93 (0.87–0.99)
WCRF/AICR score – Body fatness 0.93 (0.87–1.00) 0.96 (0.90–1.02)
WCRF/AICR score – Physical activity 0.92 (0.86–0.99) 0.94 (0.89–1.01)
WCRF/AICR score – Food promote
weight gain
0.89 (0.83–0.96) 0.92 (0.87–0.98)
WCRF/AICR score – Plant foods 0.92 (0.85–0.99) 0.94 (0.89–1.01)
WCRF/AICR score – Animal foods 0.88 (0.82–0.94) 0.91 (0.86–0.97)
WCRF/AICR score – Alcohol 0.90 (0.84–0.96) 0.93 (0.87–0.99)
WCRF/AICR score – Breastfeedingb 0.94 (0.85–1.04) 0.98 (0.88–1.08)
aCox regression model, with age at CRC diagnosis as entry time and age at
death or censoring as exit time, stratified by country and adjusted for year of
CRC diagnosis, tumor stage, tumor grade, tumor site, sex, educational level,
smoking status, plus the component that has been removed from the score.
bIn women only.
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P for heterogeneity = 0.052) (Additional files 2 and 3).
Discussion
Higher pre-diagnostic concordance with the WCRF/
AICR recommendations on diet, physical activity, and
body fatness for cancer prevention was associated with a
lower risk of CRC-related and overall death among par-
ticipants diagnosed with CRC in the EPIC cohort. Des-
pite not being able to demonstrate that meeting cancer
prevention guidelines after cancer treatment would
improve survival, what this and previous studies [13]
suggest is that having a healthy lifestyle in line with
these recommendations may improve survival among
healthy participants, and this benefit also stands in those
who develop CRC.
Concordance with the recommendations on body fat-
ness and plant food consumption assessed before diag-
nosis was associated with reduced mortality risk among
CRC patients. Body fatness and plant food consumption
are well known risk factors for CRC [21-23] and have
been also related to improved survival in CRC patients
[2,24]. The breastfeeding component was also associated
with longer survival in women diagnosed with CRC.
Breastfeeding has been associated with lower risk of de-
veloping breast cancer, ovarian cancer, type 2 diabetes,
and metabolic syndrome [25]. To our knowledge, no
previous study has reported a positive association be-
tween breastfeeding and CRC risk [26-28]. In a previous
study, meeting this special recommendation was associ-
ated with lower mortality due to cancer and circulatorydiseases among healthy EPIC participants [13]. Further
research is needed to confirm this potential beneficial
effect of breastfeeding in the mother.
In two previous studies conducted within the EPIC co-
hort, we evaluated the association of the WCRF/AICR
score with total and CRC incidence, as well as with over-
all and cancer-specific mortality, among cancer-free par-
ticipants at baseline [12,13]. One-point increment in the
WCRF/AICR score was associated with a 5% (95% CI,
3%–7%) reduction in the incidence of total cancer and
with a 12% (95% CI, 9%–16%) reduction in the incidence
of CRC [12]. Furthermore, 1-point increment in the
WCRF/AICR score was associated with a 13% (95% CI,
12%–14%) lower risk of total mortality and with a 9%
(95% CI, 7%–11%) lower risk of cancer-specific mor-
tality [13]. These findings suggest that meeting the
WCRF/AICR recommendations for cancer prevention
reduces cancer incidence and mortality among EPIC
participants free of cancer at baseline, as well as mor-
tality in EPIC participants that developed CRC during
follow-up.
A previous study based on a different cohort evaluated
the association between concordance with the WCRF/
AICR recommendations using a similar score and sur-
vival among female cancer survivors; contrary to the
present study, the score was constructed based on ex-
posure data collected on average 8.6 years after cancer
diagnosis [29]. The score was associated with lower risk
of all-cause mortality among all cancer patients, and
specifically breast cancer survivors. The association be-
tween the score and mortality among other cancer type
survivors – including CRC – was not statistically signifi-
cant; however, the number of CRC patients (n = 380)
and the number of deaths among these patients (n = 82)
was small. In that study, both the physical activity and
dietary recommendations predicted a lower mortality
risk; meeting the body fatness recommendation (i.e.,
having a healthy weight) after diagnosis was indeed asso-
ciated with a higher risk of death among cancer survi-
vors. This finding is in opposition to what is observed in
EPIC and other studies that considered pre-diagnostic
body fatness: in the present study, meeting the body fat-
ness recommendation (i.e., having a healthy weight) be-
fore diagnosis was significantly associated with reduced
mortality among CRC cases. In concordance with our
results, a previous study carried out in the same CRC
cases identified in the EPIC cohort, found that having
either general obesity or abdominal obesity before diag-
nosis was associated with a higher risk of death [24].
This obesity paradox – normal weight cancer patients at
diagnosis have worse survival than overweight or obese
cancer patients – has been previously reported and
probably reflects unintentional weight loss due to under-
lying worse health status.
Table 5 Mutually adjusted hazard ratios (HR) and 95% confidence intervals (95% CIs) for CRC-related and overall
mortality among CRC survivors, associated with the components of the WCRF/AICR score
CRC-related mortality Overall mortality
HRa 95% CI P for trendb HRa 95% CI P for trendb
Body fatness
0 1.00 (ref) 0.010 1.00 (ref) 0.006
0.5 0.88 (0.73–1.06) 0.84 (0.71–0.99)
1 0.78 (0.64–0.95) 0.78 (0.66–0.94)
Physical activity
0 1.00 (ref) 0.069 1.00 (ref) 0.162
0.5 0.86 (0.70–1.06) 0.84 (0.69–1.01)
1 0.87 (0.74–1.02) 0.91 (0.79–1.05)
Foods that promote weight gain
0 1.00 (ref) 0.683 1.00 (ref) 0.544
0.25 0.87 (0.60–1.26) 0.80 (0.58–1.10)
0.5 0.93 (0.64–1.33) 0.88 (0.64–1.21)
0.75 0.87 (0.59–1.28) 0.84 (0.60–1.17)
1 1.03 (0.64–1.69) 0.98 (0.64–1.51)
Plant foods
0 1.00 (ref) 0.069 1.00 (ref) 0.119
0.25 0.73 (0.56–0.97) 0.76 (0.60–0.97)
0.5 0.66 (0.51–0.86) 0.72 (0.60–0.91)
0.75 0.79 (0.60–1.02) 0.86 (0.68–1.09)
1 0.65 (0.49–0.87) 0.68 (0.53–0.89)
Animal foods
0 1.00 (ref) 0.156 1.00 (ref) 0.123
0.5 1.14 (0.97–1.35) 1.09 (0.94–1.26)
1 1.12 (0.83–1.51) 1.19 (0.92–1.54)
Alcohol intake
0 1.00 (ref) 0.658 1.00 (ref) 0.726
0.5 1.00 (0.78–1.28) 1.00 (0.81–1.25)
1 0.95 (0.79–1.14) 0.96 (0.82–1.12)
Breastfeedingc
0 1.00 (ref) 0.089 1.00 (ref) 0.407
0.5 0.68 (0.53–0.88) 0.76 (0.60–0.95)
1 0.80 (0.63–1.02) 0.91 (0.73–1.13)
aCox regression model, with age at CRC diagnosis as entry time and age at death or censoring as exit time, stratified by country and adjusted for year of CRC
diagnosis, tumor stage, tumor grade, tumor site, sex, educational level, and smoking status. All components were mutually adjusted for each other. bP for trend
was calculated by modelling components of the WCRF/AICR score as continuous variables. cIn women only.
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posite lifestyle score, based on a healthy diet, physical
activity, body mass index, alcohol consumption, and
smoking, measured pre-diagnosis, was associated with
improved survival after diagnosis with CRC. Specifically,
obesity was related to an increased risk of all-cause
mortality among colon cancer cases, whereas having
a healthy diet (based on a diet quality score, theHEI-2005) improved survival in rectal cancer cases.
This is in agreement with our findings. Similar to
our results, the Pelser study found evidence of effect
modification by ‘lag time’ [7]; our results suggested
that the association of a healthy lifestyle with mortal-
ity among CRC survivors tended to fade among
those with longer time periods between exposure as-
sessment and cancer diagnosis. This could be due to
Romaguera et al. BMC Medicine  (2015) 13:107 Page 10 of 12changes in lifestyle between recruitment and CRC
diagnosis or between cancer diagnosis and end of
follow-up, which were not accounted for in the present
study.
Advantages of the present study include its prospective
design, high follow-up rate, and the large number of in-
cident CRC cases included, identified within a large and
heterogeneous European population, with a diversity of
dietary patterns and other lifestyle habits. Detailed infor-
mation on multiple exposures and confounders was
available. In addition, lifestyle habits measured before
cancer incidence may represent long-term exposure to
these factors.
Limitations of our study include the lack of data on
cancer treatment; although treatment may not differ
substantially within European country, year of diagnosis,
and tumor stage – factors that were adjusted for in our
models – differences in the conduct of therapeutic inter-
ventions could be due to individual factors and health
care. Indeed, heterogeneity of findings between countries
could be partly explained by differences in therapy. Data
on tumor stage and grade was limited; we performed
sensitivity analyses excluding individuals with missing
data on these variables with no major changes in results.
Another limitation is the fact that lifestyle habits may
have changed after cancer diagnosis and we did not have
data on such changes over time. There is some evidence
indicating that some cancer patients tend to adopt
healthier lifestyle habits after treatment; however, other
studies found no considerable change in behavior
[30-34]. Therefore, we cannot assume that adherence
to cancer prevention guidelines was similar after can-
cer diagnosis in the participants of the present study.
The time interval between exposure assessment and
cancer diagnosis differed among participants, leading
to differences in ‘lag time’; however, we performed
sensitivity analyses adjusting for differences in ‘lag
time’ with no substantial change in results. Finally, as
many statistical tests were performed, we cannot rule
out that some of the statistically significant findings
were due to chance.Conclusions
In conclusion, our findings suggest that, beyond smok-
ing, a lifestyle in concordance with the WCRF/AICR
recommendations on diet, physical activity, and body
fatness, as reported by patients years before diagnosis,
can improve survival in patients diagnosed with CRC.
As expected, classical risk factors for CRC such as plant
food consumption and body fatness were associated with
CRC survival. Further research is needed to ascertain
whether adhering to these recommendations after can-
cer diagnosis have a similar effect on survival.Additional files
Additional file 1: Table S1. World Cancer Research Fund/American
Institute of Cancer Research (WCRF/AICR) recommendations for cancer
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